Peptide Receptor Radionuclide Therapy for Neuroendocrine Neoplasms in Germany: a Multi-Institutional Registry Study with Prospective Follow Up on 450 Patients

68 Ga-DOTATOC PET in patients with neuroendocrine tumors (NET). We specifically looked for incremental lesions, defined as lesions only observed on one modality even after extensive retrospective evaluation of the other modality. Methods: Twenty patients with a metastasized NET underwent 111 In-pentetreotide